Early bladder cancer serum miRNAs specific expression profile and diagnostic model

Abstract

The invention discloses an early bladder cancer serum miRNAs specific expression profile. The early bladder cancer serum miRNAs specific expression profile is composed of miR-152 and miR-148b-3p which are used for expressing up regulation as well as miR-3187-3p, miR-15b-5p, miR-27a-3p and miR-30a-5p which are used for expressing down regulation. A reverse transcription primer and a detection primer which are used for specifically expressing miRNAs in the early bladder cancer serum miRNAs specific expression profile are shown in SEQIDNO:1-13. The invention also provides an early bladder cancer serum miRNAs diagnostic model. The early bladder cancer serum miRNAs diagnostic model is calculated by utilizing the following formula: logit(P=BC)=0.439+0.1775*(miR-152)+0.0767*(miR-148b-3p)-0.475*(miR-3187-3p)-0.2395*(miR-15b-5p)-0.625*(miR-27a-3p)-0.1693*(miR-30a-5p), can be used for early diagnosis of bladder cancer and has higher diagnosis efficiency to the bladder cancer as compared with the traditional urine exfoliative cytology through ROC (receiver operating characteristic) curve analysis, and the early bladder cancer serum miRNAs diagnostic model can diagnose patients with early bladder cancer (Ta and T1).

Description

technical field [0001] The invention relates to the specific expression profile of early bladder cancer serum miRNAs, its reverse transcription primer, detection primer, and diagnostic model, and belongs to the technical field of medical diagnosis. Background technique [0002] Bladder cancer is the most common malignant tumor of the urinary system. In my country, its morbidity and mortality both rank first in urinary system tumors, and there is a gradual upward trend in recent years. 20%-30% of bladder cancer patients have myometrial invasion when they are first diagnosed, and among patients initially diagnosed with non-invasive bladder cancer, about 15% of bladder cancer patients develop invasive bladder cancer within five years. Therefore, early diagnosis and early treatment are the key to improving the prognosis and reducing the mortality of bladder cancer. Currently, the diagnostic methods for bladder cancer mainly include cystoscopy, urine exfoliation cytology, and im...

AI Technical Summary

Problems solved by technology

Although cystoscopy has high diagnostic efficiency, its invasiveness limits its wide application in bladder cancer screening; urine exfoliation cytology has high specificity but low sensitivity. Especially for low-grade tumors, the sensitivity is only 20% to 40%, and it is easily affected by the subjective factor of monitoring; CT and ultrasonography are not easy to find small lesions in the bladder, and have certain limitations in predicting the stage of bladder cancer

Images